Development and validation of a novel nerve-related prognostic model for gastric cancer based on bulk and single-cell RNA sequencing data

基于批量和单细胞RNA测序数据,开发和验证一种新型的胃癌神经相关预后模型

阅读:1

Abstract

BACKGROUND: Gastric cancer (GC) is still imposing a severe threat to human health. An increasing number of studies have found that neural activity plays an important role in the tumor microenvironment. However, the clinical implications of nerve-related genes (NRGs) remain largely unexplored. METHODS: Matched GC and adjacent normal tissue from 8 patients were collected for single-cell RNA sequencing (scRNA-seq) analysis. Gene expression and patient information were downloaded from TCGA and GEO databases. A total of 441 NRGs were collected from the KEGG database, and LASSO regression analysis was used to construct the nerve-related risk score (NRRS). The survival, immune microenvironment, and mutation analyses were then carried out. Finally, scRNA-seq analysis was used to analyze the distribution of NRGs in GC patients. RESULTS: We enrolled 441 NRGs and analyzed the association between NRGs expression and overall survival (OS). Finally, 8 NRGs highly associated with OS were identified to construct the NRRS model. Patients with low NRRS had significantly longer OS compared with high NRRS patients. We then analyzed the distribution of gene mutation landscape, enrichment annotation and immune infiltration in different NRRS subtypes. It was found that high NRRS patients displayed a significantly higher infiltration abundance of immune cell subtypes and immune checkpoint molecules. In addition, scRNA-seq was used to analyze the distribution of NRGs in 8 GC patients. We obtained 55, 052 cells in the scRNA-seq data, and the NRRS signature was significantly higher in GC tissues. EPHB3 and LPAR2 were highly expressed in epithelial cells, while NRP1, GNAI1, and SEMA6A were highly expressed in endothelial cells. CONCLUSIONS: Taken together, NRRS could serve as a stable and powerful model for survival prediction, and can help to identify GC patients who may benefit from chemotherapy and immunotherapy.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。